% with Asthma who are Obese 2013
Obesity 2013 *Includes persons who answered "yes" to the questions: "Have you ever been told by a doctor, nurse, or other health professional that you had asthma?" and "Do you still have asthma?" †Obesity status is determined by Body Mass Index (BMI in kilograms per meter squared) which is calculated by dividing respondent's weight by their height.
Does Asthma cause Obesity? Maybe

From: Obesity Is a Risk Factor for Dyspnea but Not for Airflow Obstruction
Arch Intern Med. 2002; 162(13):1477 -1481 . doi:10.1001 /archinte.162.13.1477 • 16,171 participants in NHANES III (>17yo)
• Self reported asthma, bronchodilator use and airflow obstruction (FEV1/ FVC ratio <80%)
Introduction
That the prevalence of both asthma 1 and obesity 2,3 are increasing is widely accepted. Obesity has also been proposed as a risk factor for a higher prevalence of asthma. 4 Increasing numbers of patients with asthma will be overweight, therefore, necessitating a greater knowledge of any association, in particular in response to asthma medication. Many studies have explored the relationship between asthma and obesity. In general, these have suggested: that obesity makes one more likely to develop asthma; obesity is related to worsening asthma control 5 ; clinical measures of asthma (eg, airway hyperresponsiveness [AHR] , fractional exhaled nitric oxide [FeNO] ) are affected by obesity [6] [7] [8] ; and treatment of overweight asthmatics with standard regimens may be attenuated. 9 What is clear is that any relationship between asthma and obesity is complex and unlikely to be fully explained by one particular theory.
Despite the interest in this area, no direct attention has been given to the clinical effect of obesity on the response of patients with asthma to incremental doses of inhaled corticosteroids (ICS), the mainstay of asthma control treatment. Sutherland et al 10 studied in vitro responses to glucocorticoids in overweight/obese patients with asthma. They found markers of dexamethasone response (including tumor necrosis factor) were blunted, pointing to reduced clinical efficacy of glucocorticoid therapy. Post hoc analyses of clinical trials data have also examined this. Peters-Golden et al 11 studied the effect of body mass index (BMI) on percentage of asthma control days (ACD) between 3 groups of patients with asthma receiving different asthma control medications at static doses (montelukast 10 mg/day, beclomethasone 400 g/day, or placebo). They found normal BMI patients with asthma had a Background: Although the relationship between asthma and obesity has been extensively explor effect of body mass index (BMI) on the dose-response relationship to inhaled corticosteroids (IC received little attention. Objective: To assess the dose-response of inhaled budesonide on outcome measures of asthma be overweight and normal weight patients with persistent asthma. Methods: Seventy-two patients with mild to moderate persistent asthma from a post hoc anal previously reported trial data were divided into 2 groups: overweight, BMI 25 kg/m 2 or higher; weight, BMI less than 25 kg/m 2 . Each group received 4 weeks' treatment with inhaled (hydrofluoroa budesonide 200 g/day then 800 g/day with ICS washout pretreatment. Outcome measures forced tory volume in 1 second (FEV 1 ), fractional exhaled nitric oxide (FeNO), methacholine PC20, total daily a symptom score, and overnight urinary cortisol/creatinine ratio were performed at baseline and afte dose. Results: Significantly greater improvements were seen in the normal weight group for both FeN symptom responses at 0 to 200 g and 0 to 800 g ICS doses (as change from baseline), compared w overweight group: FeNO 0 to 200 g, P ϭ .002; 0 to 800 g, P ϭ .045; symptoms 0 to 200 g, P ϭ .002; 0 g, P ϭ .013. A trend also was seen toward attenuated cortisol suppression in overweight subjects at 0 Ann Allergy Asthma Immunol 108 (2012) [237] [238] [239] [240] [241] [242] Contents lists available at SciVerse ScienceDirect values), geometric mean fold differences, or percentage changes (for within-and between-group differences). A multivariate analysis of variance was performed to assess for any cumulative type I errors inherent with multiple t tests as well as interactions between the different outcome variables with significance set at P Ͻ .05 (2-tailed). Pearson's and Spearman's correlations were performed on significant outcome variables from the between-group t tests or Mann-Whitney U tests, respectively, with BMI as a continuous (rather than categorical) variable. Differences of within-group means compared with respective baselines were assessed using paired Student's t tests (2-tailed) or related-samples Wilcoxon Signed Ranks tests. Differences between group means were assessed using independent Student's t tests (2-tailed) or independent-samples Mann-Whitney U tests. All significance levels were set at P Ͻ .05. Statistical analyses were performed using SPSS version 18.0 (SPSS Inc, Chicago, Illinois).
Results
A total of 72 patients were identified combining the 2 HFAbudesonide arms. Two independent groups were subsequently identified based on their BMI: an overweight group with BMI of 25 kg/m 2 or greater (mean, 30.0 kg/m 2 ; range, 25.1-40.5 kg/m 2 ) and a normal weight (normal) group with BMI less than 25 kg/m 2 (mean, 22.9 kg/m 2 ; range, 18.9 -24.9 kg/m 2 ). The baseline demographics for these 2 groups are presented in Table 1 . Of note, the overweight group were significantly older by approximately 9 years, with the normal group having a significantly higher baseline FeNO by approximately 13 parts per billion. Subsequent Pearson's correlation, however, demonstrated no significant effect of age (P ϭ .30) or baseline FeNO (P ϭ .24) with BMI as a continuous variable. No significant differences were found between remaining baseline values. Significant differences were observed between overweight and normal groups for both FeNO and total daily asthma symptom scores. For FeNO (Table 2) , a significantly greater reduction was seen for 0 to 200 g and 0 to 800 g budesonide in the normal group than in the overweight group (Fig. 1, Plot D) , albeit the normal group started from a higher baseline. Most of the reduction in FeNO was between 0 and 200 g of budesonide. A similar pattern was seen with symptoms (Table 3) , with significantly greater improvement in symptoms in the normal group for 0 to 200 g and 0 to 800 g of budesonide ( Fig. 1, Plot B) . Again most symptom improvement was between 0 and 200 g. Despite significant findings for FeNO and symptoms, no significant differences were seen between overweight and normal groups for methacholine PC 20 (Table 4 ; Fig 1, Plot C) although significant dose responses occurred within both groups for this measure. A nonsignificant trend toward attenuated cortisol suppression in overweight subjects was seen at 0 to 800 g budesonide (P ϭ .06) P = . P = . P = . P = . (Table 5 ). The FEV 1 response (Table 6 ; Fig 1, Plot A) showed no significant differences between weight groups for change from baseline (0 -200 g or 0 -800 g); however, a significant difference was seen between 200 and 800 g. Multivariate analysis of variance comparisons of outcome variables showed no significant interactions and confirmed an overall effect of BMI. Moreover, no confounding effect of cumulative type 1 error occurred from multiple t testing. Regression analyses of both FeNO and symptom responses at 0 to 200 g budesonide against BMI as a continuous variable show significant correlation and confirm the original between-group findings. These are presented in Figure 2 .
Discussion
We have compared data on stepwise dose-response to ICS between normal-weight and overweight patients with persistent asthma. Based on previous work suggesting reduced responsiveness to ICS in overweight patients with asthma at fixed doses, we used a variety of asthma outcome measures to assess for differvery obese patients, could reduce spirometric indices through external restriction, but we did not demonstrate this in our study. Overweight patients have a reduced functional residual capacity compared with normal-weight patients, leading to reduced airway caliber and increased airway resistance. 17 Increased elastic load on the airways also has been suggested and found to be an independent predictor of dyspnea during bronchial challenge. 18 The overweight group in our study had a mean BMI ϭ 30 kg/m 2 , which is not exceptionally high, with a difference of 7 kg/m 2 between groups; hence, it would be difficult to believe mechanical factors alone could explain the differences seen in symptoms. Indeed, a small change in FEV 1 (from the same baselines) was seen in both groups, confirming that lung mechanics is probably not the major factor to explain the disconnect between FEV 1 and symptoms. Perhaps symptoms are more closely related to airway inflammation and small airways function rather than large airway caliber, which is suggested by the connection we found between symptom and FeNO responses.
We also found a significantly greater reduction in FeNO in the 
Introduction
Asthma and obesity are major public health problem, which have been rapidly increasing in prevalence in the word (1,2). The literature suggests that there is an association between obesity and asthma. Most prospective studies show that obesity is a risk factor for the de novo diagnosis of asthma, with the risk increasing between 1.1-fold and 3-fold (3-5). Obesity is associated with a poor response to conventional asthma therapies.
Previous studies have indicated that obese subjects with asthma report greater morbidity, greater resistance to therapy, and poorer asthma control than normal-weight subjects with asthma (6-8). Overweight and obesity are associated with glucocorticoid responsiveness and with an inability to achieve adequate asthma control both with inhaled corticosteroids and combination therapies that include inhaled corticosteroids and long acting bronchodilators (9-12). In a study that was conducted by Camargo et al., compared to subjects with normal BMI, the onset to peak FEV1 may require longer treatment exposure in the very obese asthmatic patients (13). Multiple studies have found a blunted response to corticosteroids in overweight and obese asthmatics. In a study Peters-Golden et al., demonstrated that the response to inhaled corticosteroids inversely correlated with increasing BMI (14). In another study that was performed in moderate asthmatic patients, obese patients were less likely than non-obese patients to achieve asthma control with either fluticasone or fluticasone/salmeterol (9). In a study that was conducted by Forno et al., overweight and obese children had less response to budesonide compared to non-overweight children (15).
The purpose of this study was to determine the effect of obesity on response to treatment in acute asthmatic patients.
Materials and Methods
The study was carried out on adult patients in a T he prevalence of childhood obesity has increased rapidly over the last 2 decades (1-4). According to data from the National Health and Nutrition Examination Survey (1999 Survey ( -2002 , 15% of the children in the United States are at risk of being overweight and 16% are overweight (1). Along with obesity, the prevalence of childhood asthma is also increasing (5-7). The annual prevalence of self-reported asthma in children in the United States is between 4% and 8% and accounts for 6 -10% of all pediatric office visits (7). Because the increases in asthma and obesity are concomitant, it has been suggested that they may be causally related (8). Although several studies have reported a positive association between asthma and obesity in children and adults (8 -10), the results of the studies in children have not been consistent (11-13), and the exact nature of the relationship is unclear.
Status asthmaticus, or a severe asthma exacerbation, is one of the most frequent causes of admission to a pediatric intensive care unit (ICU) (5-6). In the ICU, obesity has been found to contribute to an array of medical complications including the development of multiple organ failure, prolonged ICU length of stay, and increased mortality (14 -16). Our hypothesis was that obese children admitted to the ICU with status asthmaticus similarly receive more intensive therapy and require a longer duration of hospitalization for asthma exacerbations than nonobese children.
MATERIALS AND METHODS
This study was approved by the Institutional Review Board at Connecticut Children's Medical Center, and the criteria for informed consent were waived due to its retrospective nature.
We retrospectively examined the medical records of all children between the ages of 2 and 18 yrs admitted to the pediatric ICU for treatment of status asthmaticus between April 1997 and June 2004. Children with chronic medical conditions other than asthma were excluded. Patients were identified from a previously existing database of ICU patients that is maintained by the Division of Critical Care for quality improvement purposes.
Children were classified as normal weight (Ͻ95% weight-for-age percentile) or obese (Ͼ95% weight-for-age percentile) based on reference data collected by the National Center for Health Statistics (17). We had planned to determine the body mass index (BMI) as a measure of obesity, but this was not calculated due to a lack of retrospective data regarding the height of the children involved in this study. Weight-for-age z scores were calculated using the CDC Epi Info software. Data were collected regarding basic demographics, indications for therapy, duration and level of therapy, duration of ICU and total hospitalization, and medications received. Length of stay was calculated from actual admission and discharge times.
The Objectives: Childhood obesity contributes to a wide array of medical conditions, including asthma. There is also increasing evidence in adult patients admitted to the intensive care unit (ICU) that obesity contributes to increased morbidity and to a prolonged length of stay. We hypothesized that obesity is associated with the need for increased duration of therapy in children admitted to the ICU with status asthmaticus.
Design: Retrospective cohort study. Setting: A tertiary pediatric ICU in a university-affiliated children's hospital.
Patients: We retrospectively examined data from all children older than 2 yrs admitted to the ICU with status asthmaticus between April 1997 and June 2004. Children were classified as normal weight (<95% weight-for-age percentile) or obese (>95% weight-for-age).
Interventions: None. Data expressed as mean Ϯ SD unless otherwise indicated. To identify significant predictors of ICU length of stay, a stepwise multiple regression was done in two stages. By univariate analysis, increased length of stay was associated with age (p ϭ .001), previous ICU admission (p ϭ .0005), severe persistent asthma classification (p ϭ .0005), and admission MPIS (p Ͻ .0001). Although patient race and gender were associated with obesity, these factors were not associated with increased length of stay (p ϭ .12 and p ϭ .27, respectively). The factors found to be significantly associated with ICU length of stay from the univariate analysis were entered in a stepwise procedure. Three of these (age, admission MPIS, and baseline asthma severity) continued to be statistically significant, all at p Ͻ .01. Entering obesity into this model resulted in a statistically significant improvement over the prediction achieved by the other factors (p Ͻ .05). The overall regressions and the increase in R 2 were significant after the addition of each factor (final R 2 ϭ .22). The nonstandardized and standardized regression coefficients and their associated p values for each of the final regression variables are shown in Table 3 .
Measurements and Main
DISCUSSION
Obese children have increased healthrelated problems compared with nonobese children. Childhood obesity is associated with the development of obstructive sleep apnea, type 2 diabetes mellitus, early aortic and coronary artery plaques, and significant orthopedic complications, and it is the leading cause of pediatric hypertension (20 -22) . In addition, childhood obesity is strongly associated with adult obesity (20 -22), which also carries a significant risk of serious medical complications that impair quality of life and lead to increased morbidity and mortality (23, 24) . In this study, obese children with asthma admitted to the ICU with status asthmaticus required more intensive treatment and longer durations of therapy than children of normal weight, despite adjustment for other predictors including initial severity of illness and baseline level of asthma severity.
The link between asthma and obesity is controversial (8, 9, 11, 12, 23, (25) (26) (27) (28) (29) . Although some clinicians believe that obesity may contribute to the development of asthma, associations with objec- Background: Obesity has been associated with higher risk of asthma and asthma severity both in children and adults. However, studies evaluating the relation between obesity and rhinitis have yielded conflicting results. Methods: We performed a cross-sectional study of obesity indicators and rhinitis using data from 8165 participants in the 2005-2006 National Health and Nutrition Examination Survey. Allergic rhinitis was defined as physician-diagnosed hay fever or allergy, the presence of symptoms in the past 12 months, and at least 1 positive allergen-specific IgE level. Nonallergic rhinitis was defined as a physician's diagnosis and symptoms but no positive allergen-specific IgE levels. Multivariate regression was used to assess the relationship between obesity and rhinitis in children and adults. Results: In adults, overweight or obesity was associated with increased odds of nonallergic rhinitis (adjusted odds ratio, 1.43; 95% CI, 1.06-1.93; P 5 .02). Similarly, central obesity was associated with increased odds of nonallergic rhinitis in adults (adjusted odds ratio, 1.61; 95% CI, 1.20-2.16; P < .01). In an analysis stratified by sex, the observed associations were attenuated and became nonstatistically significant in female adults but remained significant in male adults. Overweight, obesity, or central obesity were not associated with allergic rhinitis in adults. In children, central obesity was associated with reduced odds of allergic rhinitis (adjusted odds ratio, 0.35; 95% CI, 0.19-0.64; P < .01). After stratification by sex, this association was similar in female and male children. Conclusions: In adults, obesity is associated with increased odds of nonallergic rhinitis, particularly in male subjects. In children, central obesity is associated with reduced odds of allergic rhinitis, regardless of sex. (J Allergy Clin Immunol 2016; 137:1460-5.) Key words: Obesity, central obesity, allergic rhinitis, nonallergic rhinitis, National Health and Nutrition Examination Survey
Obesity and atopic diseases, such as asthma and allergic rhinitis, are major public health problems worldwide. 1,2 Multiple epidemiologic studies have shown an association between obesity and asthma in children 3-5 and adults. [6] [7] [8] [9] Although the mechanisms underlying the link between obesity and asthma are still unclear, there is growing evidence that obesity might be associated with the development of nonatopic asthma 7,10,11 but might also worsen pre-existing atopic asthma. 3, 12 Even though a high proportion of asthmatic patients also have allergic rhinitis, 13 the relation between obesity and allergic rhinitis (with or without coexisting asthma) is poorly understood. Studies of overweight or obesity and allergic rhinitis have predominantly included children and have yielded conflicting results. [14] [15] [16] [17] [18] [19] [20] [21] [22] Whereas some studies reported that neither overweight nor obesity was associated with symptoms suggestive of allergic rhinitis in children, 19 others have shown a positive association between obesity and allergic rhinitis in children and young adults, 20-22 with a few others showing a negative (inverse) association in school-aged children 14 and adult men. 17 Of interest, some studies have shown that obesity is only associated with an increased risk of allergic rhinitis in female subjects, raising the question of whether hormonal surges around puberty predispose adolescent girls to allergic sensitization and allergic rhinitis. 20, 23 Because symptoms of nonallergic rhinitis are sometimes similar to those of allergic rhinitis, 24 misclassification can occur in studies in which a diagnosis of allergic rhinitis is based solely on a physician's diagnosis without testing for allergic sensitization. Nonallergic rhinitis usually affects adults and presents with nasal symptoms. In children the most common form of nonallergic rhinitis is infectious rhinitis. 2 Nonallergic rhinitis differs from allergic rhinitis in that atopy is not involved, and thus affected patients have negative results for allergenspecific IgE, skin test reactivity to allergens, or nasal allergen challenges. 2 Although both allergic and nonallergic rhinitis are risk factors for asthma, 25 little is known about the relation between obesity and nonallergic rhinitis.
Is Obesity-Associated Asthma a Unique subtype? Probably
Cluster Membership, BMI and in vitro GC Sensitivity
Markers of in vitro GC response were assessed in 49 participants in a single center translational mechanistic substudy. In members of obese clusters 3 and 4 (n = 12), PBMC GCRa expression (pg/ng 18 s RNA, log-transformed) was significantly less than in members of the non-obese clusters 1 and 2, at 6.6 (0.3) versus 6.9 (0.3), p = 0.004, corresponding with an approximately 25% reduction in the absolute values of GCRa expression in obese asthmatics (742.8 (184.5) vs. 984.7 (276.1) pg/ng 18 s RNA, p = 0.007).
When we analyzed the correlation between log-transformed GCRa expression in all 49 participants, we observed an inverse correlation (r = 20.23) that was not statistically significant (p = 0.1). Next, due to prior reports suggesting a relationship between vitamin D and biomarkers of steroid responsiveness [20, 21] , we measured 25(OH)D concentrations in these participants. Members of clusters 3 and 4 demonstrated reduced 25(OH)D when compared with cluster 1 and 2 members, at 21.2 (7.6) vs. 29.2 (9.9) ng/mL (p = 0.01). We then analyzed the relationship between GCRaexpression and BMI in subjects who had 25(OH)D concentrations #30 ng/mL [20] . In this subset, an inverse correlation between BMI and log-transformed GCRaexpression was observed, with r = -0.52 (p = 0.02). This exploratory analysis suggested that the negative effect of BMI on GCRaexpression is augmented by 25(OH)D concentrations. Of note, 25(OH)D was not significantly correlated with GCRaexpression.
Finally, to determine if reduced GCRaexpression might be one factor leading to reduced in vitro responsiveness to GCs reported in obese asthmatics [6] , the correlation between GCRa expression (log-transformed) and MKP-1 expression both before and after exposure to dexamethasone was examined. Expression of GCRawas significantly and positively correlated with baseline (pre-DEX, log-transformed) expression of MKP-1, with an unadjusted r = 0.47 (p = 0.008, Figure 1 ) and an r = 0.47 (p = 0.004) when adjusted for 25(OH)D concentrations. A significant positive correlation between GCRa and fold-induction of MKP-1 expression by DEX was also observed, with an adjusted r = 0.38 (p = 0.03). Additionally, concentrations of hsCRP, which were increased in obese cluster members, were found to be inversely correlated with GCRa expression, with an r = 20.39 (p = 0.005, Figure 2 ). Due to small sample size in clusters 3 and 4, we were unable to demonstrate a correlation between the differential clinical response to GC and in vitro markers of GC response in clusters 3 and 4.
Discussion
The application of an hypothesis-free cluster analytical approach to a well-characterized cohort of adults with mild-tomoderate persistent asthma demonstrates that obesity is a determinant of clinical phenotype in asthma, playing a more significant role than other commonly-assessed clinical, physiologic 
Introduction
Cluster analyses of cross-sectional data from clinical populations have identified phenotypic subsets of patients with asthma, and the assessment of BMI in recent asthma cluster analyses has allowed assessment of the relationship of BMI to clinical features of asthma. Haldar and colleagues reported that obesity was associated with increased symptom expression, reduced eosinophilic airway inflammation, adult age of onset, and female sex, while also being associated with reduced clinical responsiveness to inhaled corticosteroids (ICS) [1] . A separate cluster analysis of patients participating in the NIH Severe Asthma Research Program indicated that elevated body mass index (BMI) was associated with specific clinical features in severe asthma, with the identification of a cluster of patients in whom elevated BMI was associated with female sex, adult onset asthma, a greater likelihood of complicated asthma treatment regimens, and more frequent health care utilization and need for systemic glucocorticoids (GC) [2] . These two studies have supported the conclusion that asthma phenotype is relatively homogenous in obese patients, with high symptom expression, low atopy and airway eosinophilia, and relative insensitivity to GC, a phenomenon that has been reported by others in both clinical [3] [4] [5] and in vitro [6] settings.
These reports notwithstanding, other analyses using standard comparative analytical approaches between asthmatics categorized by BMI have suggested that there is phenotypic heterogeneity among obese asthmatics, with some studies suggesting that asthma is more severe in obese asthmatics [7, 8] Background: There are a variable number of obese subjects with self-reported diagnosis of asthma but without current or previous evidence of airflow limitation, bronchial reversibility, or airway hyperresponsiveness (misdiagnosed asthma). However, the mechanisms of asthma-like symptoms in obesity remain unclear. Objectives: We sought to evaluate the perception of dyspnea during bronchial challenge and exercise testing in obese patients with asthma and misdiagnosed asthma compared with obese control subjects to identify the mechanisms of asthma-like symptoms in obesity. Methods: In a cross-sectional study we included obese subjects with asthma (n 5 25), misdiagnosed asthma (n 5 23), and no asthma or respiratory symptoms (n 5 27). Spirometry, lung volumes, exhaled nitric oxide levels, and systemic biomarker levels were measured. Dyspnea scores during adenosine bronchial challenge and incremental exercise testing were obtained. Results: During bronchial challenge, patients with asthma or misdiagnosed asthma reached a higher Borg-FEV1 slope than control subjects. Moreover, maximum dyspnea and the Borgoxygen uptake (V9O2) slope were significantly greater during exercise in subjects with asthma or misdiagnosed asthma than in control subjects. The maximum dyspnea achieved during bronchial challenge correlated with IL-1b levels, whereas peak respiratory frequency, ventilatory equivalent for CO2, and IL-6 and IL-1b levels were independent predictors of the Borg-V9O2 slope during exercise (r 2 5 0.853, P < .001).
Conclusions: A false diagnosis of asthma (misdiagnosed asthma) in obese subjects is attributable to an increased perception of dyspnea, which, during exercise, is mainly associated with systemic inflammation and excessive ventilation for metabolic demands. (J Allergy Clin Immunol 2016;137:718-26.)
Key words: Obesity, dyspnea, asthma, inflammation
Asthma and obesity are common disorders with a prevalence that has increased substantially over recent decades. Obesity is a growing worldwide problem that has reached epidemic proportions. The World Health Organization estimates that more than 600 million adults were obese in 2014.
1 Asthma is also a major health problem, which is estimated to affect about 300 million persons worldwide, with the global prevalence of asthma ranging from 1% to 18% of the general population.
2
Several cross-sectional and prospective longitudinal studies have suggested a link between obesity and asthma.
3-5 It has been reported that obesity is associated with a dose-dependent increase in the odds of incident asthma 6 and that weight reduction leads to a significant improvement in asthma symptoms.
7 Moreover, in adults with self-reported symptoms of asthma, obesity was associated with asthma severity indicators, such as respiratory symptoms, use of health care services, or medication requirements, after adjusting for potential confounders. 8 However, most of these studies have used self-reported diagnosis of asthma with no confirmation based on objective measurements of variable airflow obstruction or bronchial hyperresponsiveness. 9, 10 This raises the possibility that asthma might not be adequately diagnosed (misdiagnosed asthma). In fact, analysis of 16,171 participants from the Third National Health and Nutrition Examination Survey showed that subjects in the highest body mass index quintile had the greatest risk of exercise-related dyspnea and self-reported asthma, despite having the lowest risk for airflow obstruction.
11 Moreover, other studies have not demonstrated associations between obesity and asthma severity.
12,13 This is particularly relevant when we consider the possibility that obesity can cause dyspnea through other mechanisms, leading to a misdiagnosis of asthma.
Aside from airflow obstruction, obesity has been shown to adversely affect respiratory mechanics, decrease respiratory muscle function and lung volume, and increase the work and energy cost of breathing, 9,14 which, either independently or in combination, could also cause asthma-like symptoms. Furthermore, the perception of dyspnea can be related to other factors that are common in obese subjects, such as deconditioning 15 or psychological and emotional stress. 16 An additional possible mechanism involves the effect of inflammation on perception of symptoms. Adipose tissue from obese subjects secretes several regulatory adipokines and proinflammatory cytokines, 17 leading to a chronic mild systemic inflammatory state. 18 Several reports suggest that some of these mediators contribute significantly to neuronal mechanisms of inflammatory hypernociception 19 and org scale, subjects rated dyspnea at rest, every minute eak exercise. The Borg dyspnea scores were related to to standardize for stimulus intensity. The exercise ed as means of slopes from linear regression analysis data were used as indices of exertional dyspnea. re expressed as the x-intercepts of the relationships nd work intensity or V9O 2 . sis ple size for detection of an effect difference was evious analysis about perception of dyspnea in obese healthy subjects, reporting a slope for a 238 6 0.038 Borg/L/min. 33 Accepting an a risk of 2-sided test, 23 subjects were necessary in each group ally significant a minimum difference of 0.038 units groups, assuming that 3 groups existed (dropout s were expressed as means 6 SDs or medians epending on their distribution. Categorical variables ute numbers and percentages. Comparisons between by using ANOVA, followed by the Bonferroni post variables and the x 2 test for categorical variables. perception of dyspnea were determined by using ose significant contributors were then introduced in a r regression analysis to identify determinants of the fter verifying the assumptions of multiple regression.
the Levene test for equality of variances. In the multiple linear regression analysis predictor variables were retained only if their addition significantly improved (P < .05) the fraction of explained variability (r 2 ). A P value of less than .05 was deemed statistically significant throughout. Statistical analysis was performed with SPSS software for Windows (version 13; SPSS, Chicago, Ill).
RESULTS
Included in the study were 25 obese asthmatic subjects, 23 subjects with misdiagnosed asthma, and 27 obese control subjects. The demographic and clinical characteristics of the 3 study groups are presented in Table I . We found no significant differences between groups for anthropometric characteristics or smoking status. However, obese subjects with misdiagnosed asthma had higher trait anxiety scores (a measurement of chronic anxiety) than control obese subjects (P 5 .028).
Lung function and systemic biomarker measurements are summarized in Table II . Of the 25 asthmatic subjects, 14 had mild persistent asthma (FEV 1 > _80% of predicted value), and 11 had moderate persistent asthma (FEV 1 60% to 80% of predicted value). The asthmatic subjects had significantly lower FEV 1 and FEV 1 /forced vital capacity ratio and higher residual volume and FENO values compared with the other 2 groups. Interestingly, lung volumes and FENO values were similar between subjects with misdiagnosed asthma and control subjects (Table II) . There hic data and clinical characteristics of the study subjects*
Control group
Misdiagnosed asthma group Asthma group P value 27 23 25 -.435 16 (59) 10 (44) 11 (44) 11 (41) 13 (56) 14 (56) 7 (26) 8 (35) 7 (29) .790 re 15.6 6 11.6 26.7 6 17.4 18.9 6 12.9 .081 re 19.1 6 13.2 30.9 6 13.9 23.6 6 9.5 .042 tory score 8.6 6 7.4 14.1 6 10.5 10.9 6 7.8 .184
MI, fat-free mass index; IC, inhaled corticosteroids; LABA, long-acting b-agonists; SABA, short-acting b-agonists; STAI, State-Trait Anxiety Inventory. eans 6 SDs or numbers (percentages). rol group: P < .05.
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asthma does not seem to be a determinant because they have a degree of obesity that is similar to that of control subjects. Furthermore, the lack of differences in lung volumes or expiratory flows between the subjects with misdiagnosed asthma and control subjects supports this point. Our results confirm the hypothesis posed by identifying that the main difference between obese subjects with misdiagnosed asthma and obese control subjects lies in a higher perception of dyspnea both during the bronchial challenge and exercise to such an extent that it is similar to that of asthmatic subjects.
The main determinants of dyspnea during exercise in our obese subjects are peak ventilatory equivalent of CO 2 , peak respiratory frequency, and baseline IL-6 and IL-1b levels. The 2 former factors highlight the importance of the ventilatory response to exercise and agree with previous studies in nonasthmatic women, which observed that the perception of dyspnea in obese subjects at any given V9O 2 correlated significantly with ventilatory equivalent of CO 2 . 39 This indicates that an excessive ventilatory response for metabolic demands might be involved in the breathing discomfort of these subjects. These data are also in line with the results of Mahler et al, 40 who presented the high predictive value of breathing pattern variables, including respiratory frequency, on Borg ratings during exercise.
Nonetheless, the most striking finding of our study is the contribution of IL-6 and especially IL-1b to the perception of dyspnea during exercise in all our obese subjects. Some prior reports suggest that asthma-like symptoms are more frequent in obese subjects who present a more proinflammatory state because of the presence of metabolic syndrome. 41 This finding demonstrates the potential role of neuroinflammation in the symptomatic perception of obese subjects. In addition to the local effects of airway inflammation, release into the bloodstream of IL-1b, TNF-a, IL-6, or IL-8 caused by an increase in numbers of classically activated macrophages of obese subjects might have direct effects on the central nervous system and modify the ventilatory pattern and perception of symptoms themselves.
Inflammatory cytokines play an important role in neuroacute-phase protein reactants, in levels, and stimulation of adrenoc Although little is known about inflammatory and ventilatory co that certain cytokines, especially the generation of the respiratory p of breathing discomfort, by the ce The topographic location of IL brainstem regions that play an inte respiratory control, 20,44 and IL-1 detected in the nucleus of the sol it has been reported that systemic a a monophasic increase in ventila evokes prostanoid release in brains and the hypothalamus, where i A recent study provides evidence the mechanisms of ventilatory co tion. The intracerebroventricular increases their minute ventilati inspiratory flow and decreases response to carbon dioxide stimu FIG 1. Dyspnea during exercise in the 3 study groups. Values are means 6 SEMs. The Borg/V9O 2 slopes are significantly greater (P < .01) in subjects with asthma or misdiagnosed asthma than in nonasthmatic subjects.
FIG 2.
Correlation between the percept challenge and serum levels of adipone J ALLERGY CLIN IMMUNOL VOLUME 137, NUMBER 3 having withdrawn asthma medication. 35 This frequency is even greater in obese subjects. In subjects with emergency department visits in the past year, the odds ratio for being misdiagnosed with asthma for obese versus normal-weight subjects was 4.08 (95% CI, 1.23-13.5). 36 In fact, among 32 morbidly obese subjects with physician-diagnosed asthma, reversible airway obstruction or bronchial hyperresponsiveness was only detected in 19 patients, whereas in 13 (41%; 95% CI, 0.24-0.50) patients the diagnosis of asthma could not be confirmed.
37 Therefore an asthma diagnosis based on symptoms alone is particularly unreliable in obese subjects, and the need for objective measurements of variable airflow obstruction or bronchial hyperresponsiveness is even greater than in the general population. Otherwise, a misdiagnosis will lead to inappropriate treatment, with an increased risk of side effects and increased costs.
38
By definition, the patients of the misdiagnosed asthma group in our study had neither airflow limitation nor bronchial hyperresponsiveness, and therefore the presence of respiratory symptoms cannot be attributed to these alterations. This finding concurs with previous studies confirming that obesity increases the risk for exertional dyspnea and self-reported asthma but not for airflow limitation.
11
The mechanisms of dyspnea in obesity remain controversial. Obesity has been shown to cause a reduction in respiratory mechanics, as well as an increase in the work of breathing.
14 In obese subjects excess soft tissue weight compressing the rib cage, fatty infiltration of the chest wall, and an increase in pulmonary blood volume contribute to a reduction in respiratory system compliance.
9 When morbidly obese patients are compared with nonobese subjects, the decrease in respiratory muscle function, as well as the reduction in respiratory system compliance, results in decreased static lung volumes (particularly functional residual capacity), 14 higher oxygen cost of breathing, and a subjective increase in dyspnea. 9 The contribution of these factors to the symptoms of our subjects with misdiagnosed V9O2 (mL/kg/min) 7.0 6 1.1 4.8 6 1.3 § 4.2 6 1.6 § <.001 W (w) 30.5 6 10.7 13.7 6 11.6 § 12.5 6 6.7 § <.001 Maximal dyspnea load 5 6 1 8 6 1 § 8 6 2 § <.001
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722 CARPIO ET AL having withdrawn asthma medication. 35 This frequency is even greater in obese subjects. In subjects with emergency department visits in the past year, the odds ratio for being misdiagnosed with asthma for obese versus normal-weight subjects was 4.08 (95% CI, 1.23-13.5). 36 In fact, among 32 morbidly obese subjects with physician-diagnosed asthma, reversible airway obstruction or bronchial hyperresponsiveness was only detected in 19 patients, whereas in 13 (41%; 95% CI, 0.24-0.50) patients the diagnosis of asthma could not be confirmed. 37 Therefore an asthma diagnosis based on symptoms alone is particularly unreliable in obese subjects, and the need for objective measurements of variable airflow obstruction or bronchial hyperresponsiveness is even greater than in the general population. Otherwise, a misdiagnosis will lead to inappropriate treatment, with an increased risk of side effects and increased costs.
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AT, Anaerobic threshold; f, respiratory frequency; HR, heart rate; HRR, heart rate reserve; tI, inspiratory time; tTOT, total respiratory time; VD/VT, ratio of physiologic dead space to tidal volume; VE, minute ventilation; DVE/DV9CO2, ventilatory equivalent for carbon dioxide; VT, tidal volume; W, work intensity.
Comparisons versus the control group: P < .05, àP < .01, and §P < .001. Comparisons versus the misdiagnosed asthma group: kP < .05. {Asthma versus control groups: P 5 .096. *Values represent means 6 SDs or medians (interquartile ranges), depending on their distribution.
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9 When morbidly obese patients are compared with nonobese subjects, the decrease in respiratory muscle function, as well as the reduction in respiratory system compliance, results in decreased static lung volumes (particularly functional residual capacity), 14 higher oxygen cost of breathing, V9O2 (mL/kg/min) 7.0 6 1.1 4.8 6 1.3 § 4.2 6 1.6 § <.001 W (w) 30.5 6 10.7 13.7 6 11.6 § 12.5 6 6.7 § <.001 Maximal dyspnea load 5 6 1 8 6 1 § 8 6 2 § <.001
AT, Anaerobic threshold; f, respiratory frequency; HR, heart rate; HRR, heart rate reserve; tI, inspiratory time; tTOT, total respiratory time; VD/VT, ratio of physiologic dead space to tidal volume; VE, minute ventilation; DVE/DV9CO2, ventilatory equivalent for carbon dioxide; VT, tidal volume; W, work intensity. Comparisons versus the control group: P < .05, àP < .01, and §P < .001. Comparisons versus the misdiagnosed asthma group: kP < .05. {Asthma versus control groups: P 5 .096. *Values represent means 6 SDs or medians (interquartile ranges), depending on their distribution. Methods-A prospective study of (i) asthmatic and non-asthmatic bariatric surgery patients compared at baseline, and (ii) asthmatic patients followed for 12 months after bariatric surgery.
Results-We studied 23 asthmatic and 21 non-asthmatic patients undergoing bariatric surgery. At baseline, asthmatics had lower FEV 1 and FVC, and lower levels of lymphocytes in bronchoalveolar lavage.
Following surgery, asthmatic participants experienced significant improvements in asthma control (asthma control score 1.55 to 0.74, p < 0.0001) and asthma quality of life (4.87 to 5.87, p < 0.0001). Airways responsiveness to methacholine improved significantly (PC 20 3.9 to 7.28, p = 0.03). There was a statistically significant interaction between IgE status and change in airways responsiveness (p for interaction term = 0.01), improvement in AHR was significantly related to change in BMI in those with normal IgE (p = 0.02, R 2 = 0.46). The proportion of lymphocytes in bronchoalveolar lavage and production of cytokines from activated peripheral blood CD4 + T cells increased significantly.
Conclusions-Bariatric surgery improves airway hyperresponsiveness in obese asthmatics with normal serum IgE. Weight loss has dichotomous effects on airway physiology and T cell function typically involved in the pathogenesis of asthma, suggesting that obesity produces a unique phenotype of asthma that will require a distinct therapeutic approach.
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Obesity; asthma; bariatric surgery; weight loss; airway hyperreactivity; CD4 T cell Summary could contribute to structural changes that affect lung function. For example, a high-fat diet alters fetal lung development: rats born to mothers fed a high-fat diet during gestation have higher levels of cytokines such as tumor necrosis factor-a in their lungs, as well as increased airway resistance and decreased respiratory system compliance (31). Furthermore, mice born to mothers fed a high-fat diet have delayed fetal lung development and reduced expression of surfactant proteins (32). Consumption of a high-fat diet during gestation could contribute to the development of asthma in offspring. A high-fat diet can also alter lung structure in adult mice: structural changes are present in the airway epithelium of adult mice fed a high-fat diet (33), and collagen content in the lungs and airways is increased (34). A high-fat diet at any time from in utero development to adulthood could lead to structural and functional changes in the airway wall that could contribute to the airway disease of obesity.
The obese state could lead to asthma in those without prior airway disease in a number of different ways (Figure 1 ). These include changes in lung structure and function related to diet and mechanics, oxidative signaling, cytokine derangement, and neuronal signaling pathways. These factors may also interact with aging processes in the airway and normal population variations in the airway structure, so that although not all obese individuals develop airway disease, the greater the obesity, the higher the likelihood of developing asthma.
Pre-Existing Asthma Complicated by Obesity
On the basis of studies in human populations, there appears to be a phenotype of obese asthma that exhibits earlier onset of disease and higher markers of allergic inflammation (particularly serum IgE); in these patients, asthma symptoms, but not airway reactivity, improve with weight loss (7-9). These obese patients with asthma have approximately a threefold increased risk of hospital admission and a sixfold increased risk of intensive care unit admission, compared with their lean counterparts (8). Early-onset asthma in obese subjects, which is typically associated with elevated markers of Th2 inflammation, seems to be a particularly severe form of asthma associated with high health care use. The evolving definition of asthma Asthma affects 5-10% of the population in many developed countries and is associated with a large socioeconomic burden. Yet 'asthma' is a vague term that describes a group of clinical symptoms with reversible expiratory airflow limitation or bronchial hyperresponsiveness. Although international asthma guidelines have added "in the presence of airway inflammation" to the list of criteria for disease, inflammation is almost never measured in practice, and a consistent inflammatory process is rarely confirmed. Thus, the term asthma, like 'arthritis' , equates to a definition of grouped clinical and physiological characteristics (Fig. 1) . These characteristics could identify syndromes, phenotypes or even multiple diseases rather than a single disease. Even leading international clinical journals such as The Lancet have suggested that the term asthma is out of date and that the evolution of more detailed clinically and biologically focused definitions of this condition should be encouraged 1 . Yet, most mechanistic studies of asthma focus only on a highly specific process related to allergic airway inflammation, despite the fact that the overall importance of this single process to human disease remains poorly understood.
In the 1990s and early 2000s, this vague clinical definition of asthma led to successful clinical trials of nonspecific anti-inflammatory and bronchodilator medications. At the same time, researchers working with mouse models of allergic asthma and/or inflammation identified the crucial role of T helper (T H 2) immune pathway elements (Fig. 2) in both inflammation and airway hyperresponsiveness 2-4 . Thus, asthma was widely believed to be an allergic, eosinophilic and T H 2-mediated (and corticosteroid-responsive) disease 5-7 . Unfortunately, negative initial results from T H 2-focused human clinical trials virtually halted biological approaches to treating asthma.
Simultaneously, a subgroup of people with severe asthma were observed to have refractory disease in the absence of eosinophils, with further studies suggesting that responses of people with asthma to nonspecific anti-inflammatory drugs, such as inhaled corticosteroids, were dependent on the presence and type of airway inflammation [8] [9] [10] [11] . It was then shown that an antibody to the allergy-related factor IgE showed efficacy in reducing exacerbations in a targeted population with 'allergic' asthma 12,13 . Thus, 'asthma' began to evolve from a term describing a single disease to one encompassing multiple subgroups or, as they are now termed, phenotypes 14, 15 .
Definition of 'phenotype'
A phenotype is defined as the "observable properties of an organism that are produced by the interactions of the genotype and the environment" 16 . The concept of the phenotype have been suggested to be the prelude to that of the 'endotype' , wherein a specific biological pathway is identified that explains the observable properties of a phenotype 17, 18 . Although several endotypes of asthma have been proposed, none has been widely agreed upon; the acceptance even of asthma phenotypes is evolving, and the topic is controversial. Despite these difficulties in agreeing on endotypes, asthma phenotypes based on clinical characteristics, triggers or general inflammatory processes have been proposed, but there have been few attempts to link all of these characteristics together to better define phenotypes 19 . The definition of a true phenotype (or endotype) requires a unifying and consistent natural history, consistent clinical and physiological characteristics, an underlying pathobiology with identifiable biomarkers and genetics and a predictable response to general and specific therapies 18 ( Table 1) . Although both biased and unbiased approaches have begun to link the characteristics of asthma together to form phenotypes, no present system of subgrouping achieves all the requirements for a true phenotype or endotype. In addition, there are a number of co-morbidities and confounders that have been identified that can alter asthma phenotypes (Box 1).
